Table 2.
Characteristics of included studies.
| First Author | Year | No. | Median age (range)-year | Histological type | CAR-T type | Efficacy evaluation | Scale | Toxicity evaluation (grade ≥3) | Scale (CRS/ICANS) | Ref |
|---|---|---|---|---|---|---|---|---|---|---|
| Schuster | 2018 | 111 | 56 (22–76) | DLBCL | tisa-cel | CR: 37/93 | Lugano | CRS: 24/111 | Penn/CTCAE 4.03, MDRA 20.1 | (17) |
| PR: 11/93 | ICANS: 13/111 | |||||||||
| Schubert | 2020 | 21 | 52 (20–68) | 16 DLBCL, 3 PMBCL, 1 DHL, 1 tFL | axi-cel | CR: 9/21 | Lugano | CRS: 0/21 | ASTCT/ASTCT | (26) |
| PR: 10/21 | ICANS: 6/21 | |||||||||
| Pinnix | 2020 | 124 | 60 (18–85) | 95 DLBCL, 20 tFL, 9 PMBCL | axi-cel | CR: 60/124 | Lugano | CRS: 11/124 | ASTCT, CARTOX/ASTCT, CARTOX | (27) |
| PR: 36/124 | ICANS: 49/124 | |||||||||
| Nastoupil | 2020 | 298 | 60 (21–83) | 203 DLBCL, 76 tFL, 19 PMBCL | axi-cel | CR: 175/275 | Lugano | CRS: 19/275 | CARTOX, Lee/CARTOX, CTCAE 4.03 | (28) |
| PR: 50/175 | ICANS: 85/275 | |||||||||
| Neelapu | 2017 | 101 | 58 (23–76) | 77 DLBCL, 16 tFL, 8 PMBCL | axi-cel | CR: 55/101 | IWGRC | CRS: 13/101 | Lee/CTCAE 4.03 | (19) |
| PR: 28/101 | ICANS: 28/101 | |||||||||
| Locke | 2017 | 7 | 46 (29–69) | DLBCL | axi-cel | CR: 4/7 | IWGRC | CRS: 1/7 | Lee/CTCAE 4.03 | (29) |
| PR: 1/7 | ICANS: 4/7 | |||||||||
| Jain | 2019 | 4 | 56 (38–66) | DLBCL | axi-cel | CR: 2/4 | NP | CRS: 0/4 | NP/NP | (30) |
| PR: 1/4 | ICANS: 0/4 | |||||||||
| Abbasi | 2020 | 10 | 66 (55–77) | DLBCL | axi-cel | CR: 8/10 | NP | CRS: 1/10 | ASTCT/ASTCT | (31) |
| PR: 0/10 | ICANS: 3/10 | |||||||||
| Garfall | 2018 | 10 | 61 (48–68) | MM | tisa-cel | CR: 6/10 | IMWGRC | CRS: 0/10 | NP/NP | (32) |
| PR: 2/10 | ICANS: 0/10 | |||||||||
| Maude | 2018 | 75 | 11 (3–23) | ALL | tisa-cel | CR: 61/75 | Independent scale | CRS: 35/75 | Penn/CTCAE 4.03 | (33) |
| PR: 0/75 | ICANS: 10/75 | |||||||||
| Maude | 2014 | 30 | 14 (5–60) | ALL | tisa-cel | CR: 27/30 | Independent scale | CRS: 8/30 | Independent scale/NP | (24) |
| PR: 0/30 | ICANS: NP | |||||||||
| Schuster | 2017 | 28 | 58 (25–77) | 14 DLBCL | tisa-cel | CR: 16/28 | 1999 IWGRC | CRS: 5/28 | Penn/NP | (34) |
| 14 FL | PR: 2/28 | ICANS: 3/28 | ||||||||
| Frigault | 2019 | 8 | 50 (17–79) | 5 DLBCL, 2 HGBCL, 1 PMBCL | tisa-cel | CR: 2/8 | NP | CRS: 0/8 | Lee, ASTCT/Lee, ASTCT | (35) |
| PR: 2/8 | ICANS: 0/8 | |||||||||
| Sim | 2019 | 11 | NP | 8 DLBCL, 3 tFL, | axi-cel | CR: 5/11 | Lugano | CRS: 1/11 | CTCAE 5.0/CTCAE 5.0 | (36) |
| PR: 4/11 | ICANS: 3/11 | |||||||||
| Porter | 2015 | 14 | 66 (51–78) | CLL | tisa-cel | CR: 4/14 | IWG on CLL RC | CRS: 7/14 | Penn/CTCAE 3.0 | (37) |
| PR: 4/14 | ICANS: 1/14 | |||||||||
| Shah | 2018 | 7 | NP | 3 DLBCL, 4 FL | tisa-cel | CR: 3/7 | Lugano | CRS: NP | NP/NP | (38) |
| PR: 2/7 | ICANS: NP | |||||||||
| Wright | 2020 | 31 | NP | 26 DLBCL, 5 tFL | 18 axi-cel, 13 tisa-cel | CR: 11/27 | Lugano | CRS: 6/31 | Penn/NP | (39) |
| PR: 3/27 | ICANS: 4/31 | |||||||||
| Jacobson | 2020 | 122 | 62 (21–79) | 57 DLBCL, 33 tFL, 17 HGBCL, 8 PMBCL, 5 TMZL, 2 RS | axi-cel | CR: 61/122 | Lugano | CRS: 19/122 | Lee/CTCAE 4.03 | (40) |
| PR: 24/122 | ICANS: 43/122 | |||||||||
| Abramson | 2019 | 268 | 63 (18–86) | 206 DLBCL, 33 HGBCL, 14 PMBCL, 2FL3B | liso-cel | CR: 135/255 | Lugano | CRS: 6/268 | Lee/CTCAE 4.03 | (16) |
| PR: 51/255 | ICANS: 27/268 | |||||||||
| Fehse | 2019 | 10 | 56 (24–79) | 7 DLBCL, 3 PMBCL | axi-cel | CR: 2/10 | NP | CRS: 2/10 | ASTCT/ASTCT | (41) |
| PR: 5/10 | ICANS: 1/10 | |||||||||
| Gupta | 2019 | 78 | 60+–13※ | DLBCL | 69 axi-cel, 9 tisa-cel | CR+PR: 43/78* | NP | CRS: 10/78 | CTCAE 5.0, Lee/CTCAE 5.0 | (42) |
| ICANS: 22/78 | ||||||||||
| Korell | 2020 | 25 | 54 (20–68) | 24 DLBCL, 1 PMBCL | axi-cel | CR: 9/25 | Lugano | CRS: NP | NP/NP | (43) |
| PR: 10/25 | ICANS: NP | |||||||||
| Frey | 2019 | 35 | 34 (21–70) | ALL | tisa-cel | CR: 24/35 | Independent scale | CRS: 25/35 | Penn/CTCAE 4.03 | (25) |
| PR: 0/35 | ICANS: 2/35 | |||||||||
| Sesques | 2020 | 61 | 59 (27–75) | 38 DLBCL, 18 PMBCL, 4 tFL, 1 TMZL | 28 axi-cel, 33 tisa-cel | CR: 28/61 | Lugano | CRS: 5/61 | ASTCT/ASTCT | (44) |
| PR: 9/61 | ICANS: 6/61 | |||||||||
| Holtzman | 2020 | 45 | 60 (26–75) | 35 DLBCL, 3 PMBCL, 7 tFL | axi-cel | CR: 22/45 | NP | CRS: NP | NP/CTCAE 4.03 | (45) |
| PR: NP | ICANS: 18/45 | |||||||||
| Strati | 2020 | 100 | 60 (18–85) | LBCL (Including 77 DLBCL) | axi-cel | CR: NP | Lugano | CRS: 9/100 | CARTOX/CARTOX | (46) |
| PR: NP | ICANS:41/100 | |||||||||
| Faramand | 2020 | 75 | 63 (23–79 | 50 DLBCL, 25 Transformed Indolent lymphomas | axi-cel | CR: 36/68 | Lugano | CRS: 12/75 | ASTCT/CARTOX, ASTCT, CTCAE v4.03 | (47) |
| PR: 29/68 | ICANS: 23/75 | |||||||||
| Kittai | 2020 | 9 | 64 (40–77) | RS | axi-cel | CR: 8/8 | Lugano | CRS: 1/9 | ASTCT/ASTCT | (48) |
| PR: 5/8 | ICANS: 3/9 | |||||||||
| Deng | 2020 | 24 | 58 (24–74) | 16 DLBCL, 6 tFL, 2 PMBCL | axi-cel | CR: NP | NP | CRS: 4/24 | NP/NP | (49) |
| PR: NP | ICANS: 12/24 | |||||||||
| Dean | 2020 | 96 | 64 (19–79) | 47 DLBCL, 15 HGBCL, 5 PMBCL, 29 NP | axi-cel | CR: 74/96 | NP | CRS: 9/96 | Lee/CTCAE 4.03 | (50) |
| PR: 63/96 | ICANS: 28/96 | |||||||||
| Sermer | 2020 | 69 | 63 (19–85) | DLBCL | 47 axi-cel, 22 tisa-cel | CR: 50/69 | Lugano | CRS: NP | NP/NP | (22) |
| PR: 36/69 | ICANS: NP | |||||||||
| Wudhikarn | 2020 | 60 | 63 (20–86) | DLBCL | 43 axi-cel, 17 tisa-cel | CR: NP | NP | CRS: 7/60 | NP/NP | (23) |
| PR: NP | ICANS: 13/60 | |||||||||
| Rubin | 2020 | 204 | 60+–12※ | Inexact# | axi-cel | CR: NP | NP | CRS: NP | NP/CTCAE 4.03 | (51) |
| PR: NP | ICANS: 51/204 |
CR, complete response; PR, partial response; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; DLBCL, diffuse large B cell lymphoma; FL/tFL, follicular lymphoma or transformed follicular; PMBCL, primary mediastinal B-cell lymphoma; HGBCL, high-grade B cell lymphoma; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CAR-T, chimeric antigen receptor T; TMZL, transformed marginal zone lymphoma; MM, multiple myeloma; NP, not provided; ref, reference; MDRA, Medical Dictionary for Regulatory Activities, version; CTCAE, Common Terminology Criteria for Adverse Events; RS, Richter’ s syndrome; ASTCT, American Society for Transplantation and Cellular Therapy criteria; CARTOX, CAR-T-cell-therapy-associated TOXicity; IWGRC, International Working Group Response Criteria; IMWGRC, International Myeloma Working Group response criteria; IWG on CLL RC, International Workshop Group on CLL response criteria; Independent scale, the institution used their own criteria instead of international criteria, which can be found in original text.
*No separate CR and PR numbers were provided
※Mean ± standard deviation.
#Patients with aggressive (e.g., diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma) or indolent (e.g., follicular lymphoma, marginal zone lymphoma) histologic subtype.